Antares Pharma Inc (ATRS) Files 10-K for the Fiscal Year Ended on December 31, 2018
- By insider
Antares Pharma Inc (ATRS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Antares Pharma Inc is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies including novel, pressure-assisted injectors. Antares Pharma Inc has a market cap of $571.890 million; its shares were traded at around $3.63 with and P/S ratio of 9.72. Antares Pharma Inc had annual average EBITDA growth of 5.50% over the past five years.
Warning! GuruFocus has detected 4 Warning Signs with ATRS. Click here to check it out.
The intrinsic value of ATRS
For the last quarter Antares Pharma Inc reported a revenue of $18.8 million, compared with the revenue of $14.04 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $63.6 million, an increase of 16.6% from last year. For the last five years Antares Pharma Inc had an average revenue growth rate of 25.4% a year.
The reported loss per diluted share was 4 cents for the year, compared with the loss per share of $0.27 in the previous year. The Antares Pharma Inc had an operating margin of -26.12%, compared with the operating margin of -30.18% a year before. The 10-year historical median operating margin of Antares Pharma Inc is -48.87%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Antares Pharma Inc has the cash and cash equivalents of $27.9 million, compared with $26.6 million in the previous year. The long term debt was $25.1 million, compared with $24.9 million in the previous year. Antares Pharma Inc has a financial strength rank of 5 (out of 10).
At the current stock price of $3.63, Antares Pharma Inc is traded at close to its historical median P/S valuation band of $3.76. The P/S ratio of the stock is 9.72, while the historical median P/S ratio is 10.07. The stock gained 26.16% during the past 12 months.
Directors and Officers Recent Trades:
Director Jacques Gonella sold 200,000 shares of ATRS stock on 02/26/2019 at the average price of $3.65. The price of the stock has decreased by 0.55% since.
For the complete 20-year historical financial data of ATRS, click here.
This article first appeared on GuruFocus.
Warning! GuruFocus has detected 4 Warning Signs with ATRS. Click here to check it out.
The intrinsic value of ATRS
